Ultrasensitive fluorometric determination of daclatasvir in exhaled breath condensate samples after magnetic solid-phase extraction by carbon-coated Fe3O4 magnetic nanoparticles: method optimization via central composite design combined with desirability function

被引:0
作者
Hassan Heidari
Zahra Hassan-Zadeh
Maryam Khoubnasabjafari
机构
[1] Azarbaijan Shahid Madani University,Department of Chemistry
[2] Tabriz University of Medical Sciences,Pharmaceutical Analysis Research Center
[3] Tabriz University of Medical Sciences,Tuberculosis and Lung Diseases Research Center
[4] Tabriz University of Medical Sciences,Department of Anesthesiology and Intensive Care, Faculty of Medicine
来源
Chemical Papers | 2022年 / 76卷
关键词
Daclatasvir; Exhaled breath condensate; Magnetic nanoparticles; Carbon; Spectrofluorometer;
D O I
暂无
中图分类号
学科分类号
摘要
In this study, due to the low concentration of daclatasvir in exhaled breath condensate (EBC), for the first time, a simple, fast, sensitive, and accurate method based on magnetic nanoparticles for preconcentration of daclatasvir in EBC samples before analysis by spectrofluorometer was suggested. Magnetic nanoparticles were synthesized by the chemical co-precipitation method, and the surface of the nanoparticles was then modified by carbon through a simple hydrothermal reaction using glucose as a carbon resource. Carbon-coated Fe3O4 magnetic nanoparticles were used as adsorbents in the magnetic solid-phase extraction method. The parameters affecting the extraction efficiency, including the kind of desorption solvent, the effect of desorption time, and the volume of desorption solvent, were optimized by the univariate method. The rest of the parameters, including salt concentration, pH, adsorbent amount, and equilibrium time, were studied and optimized by a central composite design. Under the optimal conditions, a wide linear range (0.5–15 ng/mL), low detection limit (0.12 ng/mL), and excellent extraction recovery (94.80%) were obtained.
引用
收藏
页码:6619 / 6628
页数:9
相关论文
共 154 条
  • [1] Abdallah OM(2018)Development and validation of LC‐MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human plasma: application to pharmacokinetic study Biomed Chromatogr 32 1094-undefined
  • [2] Abdel-Megied AM(2018)Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method Luminescence 33 6-undefined
  • [3] Gouda AS(2021)A green homogeneous liquid-liquid microextraction method for spectrophotometric determination of daclatasvir in human plasma Sustain Chem Pharm 22 57-undefined
  • [4] Abdallah OM(2019)Molecularly imprinted polymer/reduced graphene oxide‒based carbon‒paste sensor for highly sensitive determination of the anti‒HCV drug daclatasvir dihydrochloride Sensors Actuators B Chem 283 1333-undefined
  • [5] Abdel-Megied AM(2019)Micellar spectrofluorimetric protocol for the innovative determination of HCV antiviral (daclatasvir) with enhanced sensitivity: application to human plasma and stability study Spectrochim Acta Part A Mol Biomol Spectrosc 206 369-undefined
  • [6] Gouda AS(2018)Two validated spectrofluorimeteric and high performance liquid chromatography (HPLC) methods with fluorescence detection for the analysis of a new anti-hepatitis C drug, daclatasvir hydrochloride, in raw material or tablet form and in biological fluids Luminescence 33 1118-undefined
  • [7] Abdallah IA(2022)Dibenzo-18-crown-6-based carbon paste sensors for the nanomolar potentiometric determination of daclatasvir dihydrochloride: an anti-HCV drug and a potential candidate for treatment of SARS-CoV-2 Microchem J 177 1-undefined
  • [8] Hammad SF(2016)A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma J Pharm Biomed Anal 125 194-undefined
  • [9] Bedair A(2017)Electrochemical design of a new nanosensor based on cobalt nanoparticles, chitosan and MWCNT for the determination of daclatasvir: a hepatitis C antiviral drug RSC Adv 7 13-undefined
  • [10] Mansour FR(2019)A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study J Chromatogr B 1120 24-undefined